Passage Bio assumed with an Outperform at Wedbush
Wedbush initiated coverage of Passage Bio with an Outperform rating and a price target of $4. The market sentiment has shifted, but the potential of PBFT02 for frontotemporal dementia suggests a promising valuation despite a discounted IPO.